Healthcare provider profile · identity verified

David Arisumi

Internal Medicine · WHITE OAK, PA · NPI 1366499311

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	424	138
Amlodipine Besylate	Amlodipine Besylate	321	100
Lisinopril	Lisinopril	270	85
Levothyroxine Sodium	Levothyroxine Sodium	260	78
Gabapentin	Gabapentin	221	52
Pantoprazole Sodium	Pantoprazole Sodium	219	56
Omeprazole	Omeprazole	207	61
Tamsulosin Hcl	Tamsulosin Hcl	196	54
Eliquis	Apixaban	192	35
Metformin Hcl	Metformin Hcl	186	69
Metoprolol Succinate	Metoprolol Succinate	166	51
Simvastatin	Simvastatin	149	48
Albuterol Sulfate Hfa	Albuterol Sulfate	128	39
Furosemide	Furosemide	120	36
Rosuvastatin Calcium	Rosuvastatin Calcium	120	38
Metoprolol Tartrate	Metoprolol Tartrate	119	40
Fluticasone Propionate	Fluticasone Propionate	111	29
Hydrochlorothiazide	Hydrochlorothiazide	108	36
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	105	36
Sertraline Hcl	Sertraline Hcl	105	31
Losartan Potassium	Losartan Potassium	104	34
Carvedilol	Carvedilol	102	22
Zolpidem Tartrate	Zolpidem Tartrate	98	23
Alprazolam	Alprazolam	82	23
Famotidine	Famotidine	80	17
Paroxetine Hcl	Paroxetine Hcl	76	18
Trazodone Hcl	Trazodone Hcl	75	16
Citalopram Hbr	Citalopram Hydrobromide	72	21
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	70	19
Glipizide Er	Glipizide	68	20
Potassium Chloride	Potassium Chloride	68	20
Metformin Hcl Er	Metformin Hcl	66	22
Jardiance	Empagliflozin	64	18
Allopurinol	Allopurinol	62	20
Trulicity	Dulaglutide	58	13
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	55	14
Pravastatin Sodium	Pravastatin Sodium	54	16
Prednisone	Prednisone	52	40
Atenolol	Atenolol	51	18
Duloxetine Hcl	Duloxetine Hcl	51	13
Escitalopram Oxalate	Escitalopram Oxalate	51	20
Valsartan	Valsartan	51	15
Clopidogrel	Clopidogrel Bisulfate	48	13
Alendronate Sodium	Alendronate Sodium	47	11
Ozempic	Semaglutide	47	suppressed
Clonazepam	Clonazepam	46	suppressed
Warfarin Sodium	Warfarin Sodium	46	11
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	45	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	45	12
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	42	suppressed
Donepezil Hcl	Donepezil Hcl	42	15
Montelukast Sodium	Montelukast Sodium	42	12
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	38	14
Spironolactone	Spironolactone	36	11
Lorazepam	Lorazepam	35	suppressed
Tradjenta	Linagliptin	34	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	34	suppressed
Meloxicam	Meloxicam	32	suppressed
Synthroid	Levothyroxine Sodium	32	12
Tramadol Hcl	Tramadol Hcl	32	13
Venlafaxine Hcl Er	Venlafaxine Hcl	32	suppressed
Ventolin Hfa	Albuterol Sulfate	32	12
Levetiracetam	Levetiracetam	30	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	29	suppressed
Januvia	Sitagliptin Phosphate	29	suppressed
Naproxen	Naproxen	29	11
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	28	suppressed
Buspirone Hcl	Buspirone Hcl	27	suppressed
Diazepam	Diazepam	27	suppressed
Ezetimibe	Ezetimibe	27	suppressed
Latanoprost	Latanoprost	26	suppressed
Ropinirole Hcl	Ropinirole Hcl	26	suppressed
Humalog Kwikpen U-100	Insulin Lispro	25	suppressed
Ibuprofen	Ibuprofen	25	suppressed
Bupropion Hcl Sr	Bupropion Hcl	24	suppressed
Baclofen	Baclofen	23	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	23	suppressed
Glipizide	Glipizide	23	suppressed
Humulin N	Insulin Nph Human Isophane	23	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	23	18
Rizatriptan	Rizatriptan Benzoate	23	suppressed
Meclizine Hcl	Meclizine Hcl	21	suppressed
Bumetanide	Bumetanide	20	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	20	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	20	suppressed
Finasteride	Finasteride	19	suppressed
Propranolol Hcl	Propranolol Hcl	19	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	18	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	18	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	17	17
Breo Ellipta	Fluticasone/Vilanterol	17	suppressed
Felodipine Er	Felodipine	17	suppressed
Glimepiride	Glimepiride	17	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	17	suppressed
Tizanidine Hcl	Tizanidine Hcl	17	suppressed
Valacyclovir	Valacyclovir Hcl	17	suppressed
Bupropion Xl	Bupropion Hcl	16	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Mirtazapine	Mirtazapine	16	suppressed
Nifedipine Er	Nifedipine	16	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	16	suppressed
Ketoconazole	Ketoconazole	15	suppressed
Nystatin	Nystatin	15	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	15	suppressed
Carisoprodol	Carisoprodol	14	suppressed
Benazepril Hcl	Benazepril Hcl	13	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Ibu	Ibuprofen	13	suppressed
Arnuity Ellipta	Fluticasone Furoate	12	suppressed
Desmopressin Acetate	Desmopressin Acetate	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	12	suppressed
Methocarbamol	Methocarbamol	12	suppressed
Methylprednisolone	Methylprednisolone	12	suppressed
Sucralfate	Sucralfate	12	suppressed
Xarelto	Rivaroxaban	12	suppressed
Celecoxib	Celecoxib	11	suppressed
Lithium Carbonate Er	Lithium Carbonate	11	suppressed
Nitroglycerin	Nitroglycerin	11	suppressed
Risperidone	Risperidone	11	suppressed
Solifenacin Succinate	Solifenacin Succinate	11	suppressed
Topiramate	Topiramate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error